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INTRODUCTION
Neuropsychiatric disease may occur
commonly in mixed connective tissue dis-
order (MCTD) and has been observed in
up to 55 percent of patients. Aseptic
meningitis has been described as the most
common presentation, although psychosis,
convulsions, peripheral neuropathy,
trigeminal neuropathy, and cerebellar
ataxia have also been described [1, 2].
Corticosteroid therapy is highly effective
in the management of CNS and systemic
MCTD but may independently cause
mood disturbances and psychosis; there-
fore, clinicians must carefully distinguish
this entity from primary CNS disease [3-
5]. Lupus cerebritis and steroid psychosis
occurring in patients with systemic lupus
erythematosus (SLE) has been reported
[6] but has not previously been described
in mixed connective tissue disorder.
Herein we describe an individual with
MCTD demonstrating both CNS MCTD
and steroid-induced psychosis over two
consecutive hospitalizations.
CASE REPORT
A 38-year-old African-American
female with a five-year history of mixed
connective tissue disorder (positive anti-
RNP, ANA, anti-dsDNA, anti-Sm) and no
prior psychiatric history presented to our
hospital with altered mental status and
MCTD flare. She had been clinically sta-
ble on prednisone 5 mg daily, plaquenil
200 mg twice daily, and ibuprofen as
needed for several years. Nearly two
months prior to admission, she began
experiencing gradual worsening of her
disease with more severe esophageal dys-
motility and Raynaud's symptoms.
Laboratory monitoring revealed mild ele-
vations in ESR. The prednisone dose was
increased to 5 mg each morning and 2.5
mg each evening two to three weeks prior
to admission. In anticipation of starting
methotrexate, liver function tests were
obtained, and found to be mildly elevated.
An abdominal ultrasound and CT of the
abdomen/pelvis were normal.
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New Haven, ConnecticutShe was admitted with high fevers,
arthralgias, myalgias, severe esophageal
dysmotility and Raynaud's symptoms,
generalized weakness and fatigue, and a
two to three week history of progressive
alteration in mental status. This was
described by family members as a marked-
ly slow, labored speech, lack of insight
into surrounding environment, nonsensical
speech, poor concentration, emotional
lability, and loss of inhibition. She was
noted to carry conversation with imagi-
nary figures, and chew on gum without
first removing the wrapper. There was no
history of substance abuse, tick bites, other
toxic or outdoor exposures, or trauma. 
Her exam was notable for fevers
(102.3°F), mild tachycardia (HR 90), pro-
found photophobia, multiple new erythe-
matous plaques on bilateral cheeks in a
malar distribution, old-neck poikiloderma,
swollen hands and lips, mildly enlarged
nontender liver, and synovial thickening in
joints of hand and feet. Laboratory studies
revealed anemia (Hg 8.8), leukocytosis
(15,700), transaminitis (SGPT 66, SGOT
190), elevated ESR (113), and elevated
CPK (1088). Disease activity was marked
by positive ANA titer of 1:10,240 in
homogenous pattern and diminished com-
plement levels (C3<28, C4<10). Initial
CSF studies demonstrated aseptic menin-
gitis with monocytic pleocytosis (WBC
20, 100 percent monocytes, protein 40,
glucose 51). All bacterial and viral cul-
tures, India ink stain, RPR, and AFB were
negative. Multiple imaging studies includ-
ing a CT head, MRI brain, and EEG were
also unremarkable. A diagnostic evalua-
tion of elevated liver enzymes revealed
negative HIDA scan and CT abdomen. In
addition, initial ELISA screening for HIV
was positive while the Western blot found
to be indeterminate. Repeat testing of
ELISA and Western blot, p24 antigen, and
HIV PCR were subsequently confirmed to
be negative.
She was diagnosed with MCTD dis-
ease flare with cerebritis, myositis, and
hepatitis, and managed with an increase in
corticosteroids to prednisone 40 mg daily.
Over the course of a one-week hospitaliza-
tion, the patient experienced significant
improvement in her constitutional and
rheumatologic symptoms as well as pro-
gressive normalization of her mental state
to baseline. Due to a clinical suspicion for
possible underlying HSV encephalitis, she
was empirically treated with intravenous
acyclovir, followed by oral famciclovir.
HSV PCR testing was subsequently found
to be negative. She was discharged in sta-
ble condition on prednisone 20 mg twice
daily and plaquenil 200 mg twice daily.
She was re-admitted to our hospital
seven days later with a three-day history of
new mental status changes. In contrast to
prior hospitalization, she was described by
family members as hyperverbal with pres-
sured speech, loosening of associations,
flight of ideas, markedly elevated mood
with euphoria and delusions of grandeur,
significantly increased energy, sleepless-
ness, hyper-religiosity, and delusions of
divine revelations. She described opening
a multi-million dollar internet business to
pay off debts of her friends and extended
family, referred to a memoirs of her life on
The New York Times bestseller list, and
spoke under the pretense of divine author-
ity. She reported no other complaints, and
described marked improvement in all joint
symptoms, esophageal dysmotility,
Raynaud's symptoms, and skin disease,
and denied the presence of fevers, chills,
sweats, headaches, visual changes, or a
stiff neck.
Upon examination, she was found to
be hyperactive, pacing back and forth
across the examination room, and hyper-
verbal with pressured speech. She repeat-
edly called to an imaginary dog outside the
room, demonstrating active auditory and
visual hallucinations. Her exam was
notable for a normal temperature, mild
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ment in her rash across the nasal bridge
and bilateral cheeks, old poikiloderma of
neck, minimal photophobia, absence of
hand edema, and a normal abdominal
exam. Laboratory data revealed continued
anemia (Hg 7.8), normal chemistries and
urinalysis, and minimally elevated ESR
(45).
Following a formal psychiatric evalu-
ation, a diagnosis of steroid-induced
mania/psychosis was made. The pred-
nisone dose was reduced from 20 mg
twice daily to 20 mg once daily over sev-
eral days, followed by 10 mg once daily at
time of discharge. This was accompanied
by the addition of a steroid-sparing
immunosuppressive agent, azathioprine 50
mg twice daily, to prevent MCTD exacer-
bation, as well as a low-dose anti-psychot-
ic to control her manic symptoms.
Haloperidol 5 mg twice daily was initiated
and quickly tapered to an as needed dosing
schedule upon discharge. Her mental state
progressively improved with near-normal-
ization to baseline over a one-week period.
Follow-up visits to her primary care physi-
cian two weeks and several months later
demonstrated full normalization of her
mental state and behavior off anti-psy-
chotics and on a tapered dose of pred-
nisone.
DISCUSSION
Our patient provides substantial evi-
dence for two distinct manifestations of
neuropsychiatric disease, one likely attrib-
utable to primary CNS involvement of
MCTD and the other secondary to corti-
costeroid effect. Although neuropsychi-
atric disease appears to be common in con-
nective tissue disorders, occurring in
approximately 50 to 75 percent of patients
with SLE [7, 8], and up to 55 percent of
patients with MCTD [1], steroid-induced
psychosis is uncommon. The condition is
observed in less than 5 percent of patients
with SLE [9] whereas its incidence in
MCTD is unknown. The presence of CNS
lupus and steroid psychosis in a patient
with SLE has been previously reported by
Hirohata and colleagues [6]. We believe
this is the first reported case of both man-
ifestations occurring in a patient with
MCTD. 
In the first episode, our patient pre-
sented with aseptic meningitis and other
symptoms highlighting an exacerbation of
her underlying mixed connective tissue
disorder. This is corroborated by a congru-
ence of historical factors (increased
esophageal dysmotility, Raynaud's symp-
toms, articular complaints), exam findings
(new rash, profound photophobia, hand
edema, and articular disease), and labora-
tory markers (markedly increased ESR,
transaminitis, and elevated CPK). In this
setting, concomitant alterations in mental
status were appropriately attributed to pri-
mary CNS involvement, particularly in
light of a typical presentation for CNS
MCTD. Aseptic meningitis (monocytic
pleocytosis) is well-described as the most
frequently observed sign of CNS involve-
ment in MCTD, representing 20 percent of
cases [1] More importantly, neuropsychi-
atric and somatic complaints improved in
tandem upon initiation of aggressive corti-
costeroid therapy, further confirming the
diagnosis. In the second episode, she pre-
sented with symptoms of frank mania,
with profound euphoria, hyperverbality
and pressured speech, sleeplessness, and
delusions of grandeur. Historical factors
(improved joint and skin symptoms,
decreased esophageal dysmotility and
Raynaud's), exam findings (healing rash,
absence of hand edema, minimal photo-
phobia), and laboratory markers (low ESR
45) clearly demonstrated improved, stable
MCTD disease.  Considering the context
in which these mental status changes
occurred (within one week of a significant
increase in prednisone and in a setting of
low disease activity), a corticosteroid-
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diagnosis. This is further supported by sig-
nificant clinical improvement upon steroid
taper. 
Steroid psychosis, the product of
steroid-induced vulnerability of hip-
pocampal neurons to metabolic insults
[10], most commonly presents with severe
depression or frank mania. Symptoms of
psychosis are less common, occurring in
approximately 13 percent of patients.
Most patients (57 percent) demonstrate
these changes soon after starting or
increasing corticosteroids, usually within
the first two weeks, and typically at doses
exceeding 40 mg daily (77 percent).
Steroid taper is nearly always adequate in
managing this syndrome (92 percent),
although neuroleptics can be helpful.
Symptom duration after initiating the taper
is variable, although has a mean of 21 days
[5]. In our patient, onset of manic symp-
toms began one to two weeks after dose
increase, occurred at a total dose of 40mg
daily, and responded to slow prednisone
taper, albeit with support of a low-dose
antipsychotic and steroid-sparing
immunosuppresant. She returned to base-
line mental state over a one to two-week
period.
One may argue that external factors
surrounding each episode may have con-
tributed to our patient’s neuropsychiatric
disease. Many medications other than cor-
ticosteroids have been implicated as eti-
ologies of acute mental status change in
patients with rheumatologic disorders.
Nonsteroidal anti-inflammatory agents, in
particular, may induce an aseptic meningi-
tis in patients with mixed connective tissue
disorder, This has been reported in patients
using therapeutic doses of ibuprofen [11,
12] and sulindac [13]. Accurate account-
ing of ibuprofen doses consumed by our
patient prior to her first episode is not
available and not specifically reported by
the patient. No ibuprofen was used
between initial discharge and second hos-
pitalization. One would predict that in a
state of increased disease activity on a sub-
therapeutic dose of corticosteroids, the
number of breakthrough doses of ibupro-
fen would have increased. In the absence
of this data, no conclusion can be made,
although it is unlikely that in a setting of
disease flare (and high incidence of neu-
ropsychiatric disease in MCTD) that
NSAIDs alone were responsible for her
presentation with aseptic meningitis. More
significantly, literature reveals that
NSAIDs cannot account for her symptoms
of psychosis in the first episode nor mania
in the second.
HIV disease, too, can dramatically
alter the differential diagnosis and man-
agement approach in a patient presenting
with mental status changes.  The initial
positivity of HIV screening in our patient
presented the medical team with several
challenges, including proper assessment of
the test's accuracy and clinical signifi-
cance, and providing fair, objective coun-
seling to the patient regarding these
results. False positivity of ELISA testing
and indeterminate Western blot results are
well-described in patients with SLE [14]
but is less certain in patients with MCTD.
Clinicians must exercise caution in test
interpretation in these patients, and must
consider alternative diagnostic approaches
for HIV infection [15]. HIV infection has
been described as the new “great mimic”
and certainly can present with neuropsy-
chiatric disease [16] or manifestations of
rheumatologic disease [17]. Notably,
mixed connective tissue disorder, in par-
ticular, has profound clinical similarities
with HIV infection. Anti-RNP antibodies
cross-react with the HIV-1 surface due to
multiple homologies between the gp
120/41 envelope complex and the 70 K
protein of U1 snRNP, resulting in the abil-
ity of anti-RNP sera to effectively inhibit
HIV-1 infectivity in vitro [18]. MCTD
may, in fact, elucidate new strategies for
development of immunologic resistance to
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Fortunately, our patient was subsequently
confirmed HIV-negative after repeat test-
ing with standardized commercial assays,
p24 antigen, and HIV PCR, and therefore
HIV infection was an unlikely contributor
to her neuropsychiatric disease.
One can additionally argue that pri-
mary CNS disease and steroid psychosis in
our patient represented SLE rather than
MCTD. This is clinically important in
light of unique differences in natural histo-
ry of disease and prognosis. Specifically,
MCTD is characterized by significantly
less renal disease [19, 20] and less mor-
bidity and mortality from neuropsychiatric
disease [21] but more severe arthritis and
Raynaud's phenomenon, as well as an
increased risk of death due to pulmonary
hypertension [22-24]. Although this does
not diminish the uniqueness of the case,
the precarious nature of MCTD as a
unique disease entity underlies the uncer-
tainty in establishing a definitive diagno-
sis. MCTD is appropriately described as
an undifferentiated connective tissue dis-
order (CTD) or “overlap” syndrome char-
acterized by combinations of clinical fea-
tures of SLE, systemic sclerosis,
polymyositis/dermatomyositis (PM/DM),
and rheumatoid arthritis [25]. Although
several classification schemes have been
described in literature, including three sets
of criteria (Alarcon, Kasukawa, and
Sharp), it is distinguished by the presence
of high titer ANAand circulating autoanti-
bodies to nuclear RNP antigen [26-28].
The natural history of MCTD predicts that
within five years, nearly one-quarter of
patients will manifest characteristic fea-
tures of one of its four related connective
tissue disorders [29], most commonly sys-
temic sclerosis (21 percent), and less com-
monly SLE and rheumatoid arthritis [30].
One can hypothesize, therefore, that our
patient differentiated from an “overlap”
syndrome of MCTD into dominant SLE.
SLE disease is suggested by the pres-
ence of anti-dsDNA and anti-Sm antigen
in her serum. Although previous authors
have used the presence of anti-Sm antigen
as an exclusion criterion for MCTD [28],
it is now clear that this antibody is not spe-
cific for SLE and that both anti-dsDNA
and anti-Sm antibodies can be seen tran-
siently in patients with MCTD [31].  More
importantly, our patient demonstrated
MCTD disease by the characteristic pres-
ence of both anti-RNP antibodies and high
ANAtiters (1:10,240). Titers in MCTD are
significantly higher (usually >1:2,560)
than those observed in SLE [32] and are
commonly used to distinguish the two
clinical entities [33, 34]. Additionally, by
definition, patients with MCTD have fea-
tures of several connective tissue disor-
ders; in fact, most patients with MCTD
will fulfill diagnostic guidelines for SLE
[35] and rheumatoid arthritis [36]. By
manifesting signs of systemic sclerosis,
SLE, and PM/DM, our patient clearly
remains within the definition of MCTD as
an “overlap” syndrome, distinct and inde-
pendent of SLE.
CONCLUSION
Neuropsychiatric disease may occur
commonly in patients with MCTD and can
manifest as primary CNS disease or
steroid-induced psychosis in the same
patient. CNS MCTD presents most com-
monly as aseptic meningitis, in contrast to
steroid-induced psychosis, which is char-
acterized by severe mania or depression.
Clinicians must carefully consider other
secondary causes of mental status changes
in these patients, including medications,
metabolic derangements, and other comor-
bid conditions. The natural history of
MCTD is dissimilar to its individual
CTDs, and thus monitoring for differentia-
tion is an important component of long-
term management. Low-dose anti-psy-
chotics and steroid-sparing immunosup-
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adjuncts to steroid taper in the manage-
ment of steroid-induced psychosis.
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